Research & development > Clinical diagnostics

Insulin synthesis without using E.coli

30 October, 2005

If living cell is replaced by a test-tube with DNA and a set of substances, it is possible to get proteins in a more simple and inexpensive way. That was done by Russian biochemists synthesising insulin without help of transgene Escherichia coli.


Development of a quick detection method for complex immune analytes

29 October, 2005

An analysis method permitting the simultaneous quantification of numerous parameters in the immune system was recently presented at the Campus Vienna Biocenter. The technology, which has been developed by Bender MedSystems, is based on the principle of a widespread analysis device and thus allows for rapid implementation in daily laboratory life. It thus succeeds in satisfying the growing demand at clinical and pharmaceutical organisations for increasingly efficient analysis methods at favourable costs.


Genes may predict response to ADHD medication

27 October, 2005

Testable genetic differences might be used to predict the effectiveness of a medication commonly prescribed to treat attention deficit hyperactivity disorder, a new study suggests.


Oncogene may lead to predictive test

25 October, 2005

Researchers at The University of Texas MD Anderson Cancer Centre say they have discovered a potential oncongene in ovarian cancer, which is the leading cause of gynaecological cancer death in US women.


Portable generic risk detection

24 October, 2005

A portable biosensing device based on micro- and nanotechnologies is expected to help doctors rapidly and accurately forewarn patients of their genetic risk of developing diseases such as cancer.


Microchips for in vitro diagnostics

21 October, 2005

DiagnoSwiss and bioMerieux have signed an exclusive licence agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics.


Investment to develop pain therapy

20 October, 2005

A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.


Salivary bacteria as indicators of oral cancer

18 October, 2005

Patients suffering from oral cancer have increased levels of certain bacteria in their saliva, according to research published in the Open Access journal, Journal of Translational Medicine. Six common species of bacteria were found at significantly higher levels in the saliva of patients with oral squamous cell carcinoma (OSCC) than in the saliva of healthy individuals. The researchers were able to use three of the six species as a diagnostic tool to predict more than 80% of oral cancer cases. These preliminary findings indicate that three species of bacteria may be incidentally or causally linked with OSCC, and if so detection of these species could be used as a simple, rapid and non-invasive saliva test to diagnose oral cancer.


A wee step forward

12 October, 2005

Physicists in Singapore have created the first paper battery that generates electricity from urine.


Banana and mosquito research

13 August, 2005

Two researchers from Queensland are contributing to a $436 million global plan to improve the health of millions of people in some of the world's poorest countries.


Dye to pinpoint diseases

23 May, 2005

University of Toronto researchers have designed a chemical screening tool that will light up when dangerous pathogens and diseases in air, water and bodily fluids are present.


Research aids coughing

13 April, 2005

UTS Professor Ashley Craig is involved in a project in the NSW Premier's spinal chord injury (SCI) research program to develop an electrical stimulus to help quadriplegics cough.


Keeping frog disease under control

11 April, 2005

A workshop on new methods of detecting and controlling the spread of one of the world's most deadly frog diseases – chytridiomycosis – was recently held at CSIRO Livestock Industries' Australian Animal Health Laboratory (AAHL) in Geelong, Victoria.


Cell processing facility contracted for clinical trials

16 February, 2005

Australia’s adult stem cell company, Mesoblast has signed an agreement for production of specialised adult stem cells, known as Mesenchymal Precursor Cells (MPCs), to be used in human pilot clinical trials in patients with orthopaedic and cardiovascular diseases.


Bird flu vaccine on way

27 August, 2004

CSIRO Livestock Industries has developed an experimental vaccine to protect chickens from the deadly H5N1 strain of avian influenza (bird flu).


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd